Proportion of Decedents' Expenditures Among Recent Reductions in Medicare Expenditures
Health care expenditures continue to increase in the United States. Historically, end-of-life expenditures have been a consistent contributor to that growth.
1 Recent studies of end-of-life practice patterns suggest that increased use of hospice care costs more than it saves, 2 end-of-life care intensity is increasing, 3 and end-of-life intensive care unit use and care transitions are increasing, 4 raising concerns that end-of-life care costs might be accelerating.
To investigate such concerns, we used publicly available Medicare data to calculate changes in end-of-life Medicare expenditures in the recent past.
Methods | Dartmouth College has determined that analysis of Dartmouth Atlas data is not considered human subjects research. From the Dartmouth Atlas Project website (http: //www.dartmouthatlas.org), for fee-for-service Medicare enrollees aged 65 to 99 years, we obtained publicly available per-capita mean annual 2004 through 2014 Medicare part A and B expenditures for all enrollees and mean prior 2-year expenditures for enrollees who had a chronic condition and died in that year (decedents). From total fee-for-service expenditures (number of enrollees times the mean annual percapita expenditure), we subtracted total annual expenditures for decedents (the number of decedents times the mean prior 2 years' expenditures) to estimate survivors' expenditures.
Using the consumer price index to convert expenditures to 2014 dollars, for decedents and survivors, we calculated the annual overall per-capita expenditures in 6 categories: inpatient (including hospital and skilled nursing facility expenditures), physician, outpatient, home health, hospice, and durable medical equipment. We calculated year-to-year changes in Medicare expenditures attributable to changes in the numbers of survivors or decedents (changes in numbers Discussion | Contrary to other studies, we found that per-capita end-of-life spending is decreasing and appreciably contributing to overall per-capita Medicare spending growth moderation. Endof-life spending reductions were driven by substantially lower inpatient care expenditures (and modestly lower physician and home health expenditures) without commensurate increases in other care segments. Potential explanations include both changes in supply (physician efforts may have been redistributed to the newly insured following implementation of the Affordable Care Act) and demand (normalization of more conservative end-oflife preferences, or even financial constraints imposed by the Great Recession 6 ). While our findings are limited because they used administrative data sets, examined only the fee-for-service Medicare population, could not examine components of inpatient care, and did not study specific patients and their end-of-life spending patterns, 5 they warrant further investigation into why end-of-life care intensity is changing and, particularly, how those changes influence end-of-life care quality. 
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Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin
Rising brand-name pharmaceutical expenditures can be significantly mitigated with generic substitution, particularly for high-volume categories, such as statins.
1,2 Pfizer's Lipitor (atorvastatin calcium) was the best-selling drug of all time until a generic version bec ame available in the United States in November 2011.
3 However, national use of Lipitor and the financial impact of generic availability are unknown. Therefore, we analyzed trends in use and expenditures associated with Lipitor after generic atorvastatin availability. (Table) . Lipitor use decreased from 3.9 million adults in 2012 to 0.7 million adults in 2014, with a concomitant increase in uptake of generic statin from 8.6 million in 2012 to 14.3 million in 2014. In this time period, total atorvastatin-associated expenditures decreased from $7.0 billion to $5.4 billion. Total national expenditures associated with Lipitor were $3.5 billion (50% of total atorvastatin cost) in 2012 vs $357 million (7% of total cost) in 2014. Excess expenditure associated with continued Lipitor use totaled $2.1 billion from 2012 to 2014 (Figure) . More than half (57%) of excessive spending ($1.2 billion) was noted among patients with Medicare or Medicaid, who accounted for 58% of Lipitor users. We found that peruser total expenditure for Lipitor were higher compared with generic throughout 2012 to 2014. However, in 2014, Lipitor peruser OOP cost was lower than generic atorvastatin ($27 vs $49).
Discussion | Availability of generic atorvastatin led to a 28% reduction in atorvastatin-associated expenditures from 2012 to 2014, despite a 20% increase in overall atorvastatin use in the United States. However, persistent prescription of Lipitor resulted in $2.1 billion in excess expenditure from 2012 to 2014.
A report in a privately insured cohort showed that Lipitor prescription resulted in high OOP costs in the 6 months of generic exclusivity given limited competition.
3 Our study adds to this report by providing national estimates of expenditures associated with Lipitor from both private and publically financed insurance programs, showing more than $110 million in excess expenditures on Lipitor beyond the first year of generic introduction. Furthermore, we found that Lipitor OOP cost was lower than that of generic in 2014, likely owing to deals made with pharmacy benefit managers to lower Lipitor copays below that of generics. 
